证券代码：300858 证券简称：科拓生物 公告编号：2025-016 北京科拓恒通生物技术股份有限公司 关于作废部分已授予尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开的第三届董事会第十三次会议、第三届监事会第十二次会议，审议通 过《关于作废部分已授予尚未归属的限制性股票的议案》。现将相关内容公告如 下： 一、2024 年限制性股票激励计划已履行的相关审批程序 1、2024 年 2 月 2 日，公司召开第三届董事会第五次会议，审议通过《关于 <北京科拓恒通生物技术股份有限公司 2024 年限制性股票激励计划（草案）>及 其摘要的议案》《关于<北京科拓恒通生物技术股份有限公司 2024 年限制性股票 激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办理 2024 年限制性股票激励计划相关事宜的议案》，关联董事已回避表决。 2、2024 年 2 月 2 日，公司召开第三届监事会第五次会议，审议通过《关于 <北京科拓恒通生物技术股份 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥77,612,862.67, representing a 31.49% increase compared to ¥59,025,584.73 in the same period last year[5] - Net profit attributable to shareholders was ¥20,329,624.63, up 9.79% from ¥18,516,444.83 year-on-year[5] - Basic earnings per share increased by 14.29% to ¥0.08 from ¥0.07 in the same period last year[5] - Total operating revenue for the current period reached ¥77,612,862.67, a significant increase of 31.5% compared to ¥59,025,584.73 in the previous period[27] - Net profit for the current period was ¥20,329,624.63, representing an increase of 9.8% from ¥18,516,444.83 in the previous period[28] Cash Flow - The net cash flow from operating activities was negative at -¥529,716.47, a decline of 101.84% compared to ¥28,714,195.39 in the previous year[14] - The company's cash flow from operating activities showed improvement, with a notable increase in cash inflows compared to the previous period[29] - Operating cash inflow totaled $66,962,274.75, down 24.0% from $88,076,558.40 in the previous period[30] - Operating cash outflow increased to $67,491,991.22, up 13.5% from $59,362,363.01 in the previous period[30] - Net cash flow from operating activities was negative at -$529,716.47, compared to a positive $28,714,195.39 in the previous period[30] - Cash inflow from investment activities was $456,343,362.38, a decrease of 25.3% from $611,003,135.92 in the previous period[31] - Net cash flow from investment activities increased to $102,761,836.24, up 71.5% from $59,957,195.27 in the previous period[31] - Cash outflow for purchasing fixed assets and intangible assets was $95,438,950.78, up 76.6% from $54,078,280.88 in the previous period[31] - Cash outflow from financing activities was $416,094.00, a significant decrease from $3,470,324.71 in the previous period[31] - The net increase in cash and cash equivalents was $101,816,024.92, compared to $85,201,065.95 in the previous period[32] - The ending balance of cash and cash equivalents was $207,401,392.39, down from $273,737,504.09 in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,932,060,722.81, a 0.86% increase from ¥1,915,597,694.39 at the end of the previous year[5] - Non-current assets totaled ¥858,551,717.68, down from ¥960,892,687.72 in the previous period, indicating a decrease of 10.6%[25] - Current liabilities decreased slightly to ¥94,114,470.60 from ¥96,188,516.35, a reduction of 2.2%[25] - The total current assets increased to ¥1,073,509,005.13 from ¥954,705,006.67, representing a growth of approximately 12.4%[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,685[16] - The largest shareholder, Sun Tiansong, holds 19.94% of shares, totaling 52,538,822 shares[16] - The top ten shareholders hold a combined total of 70.93% of the shares, indicating a concentrated ownership structure[16] - The company has no preferred shareholders or changes in restricted shares during the reporting period[18] Investments and Future Plans - The company reported a significant increase in investment income, which rose by 250.54% to ¥982,169.09 from ¥280,184.64 year-on-year[11] - The company plans to continue expanding its business in the probiotics and micro-ecological preparations sectors, which have shown significant growth[11] - The company plans to adjust the investment scale and structure of the food sector R&D production base project, reallocating surplus funds of ¥62.58 million to supplement working capital[21] - The project is expected to reach a usable state by December 31, 2026[21] - The company plans to expand its market presence and invest in new technologies to drive future growth[29] Research and Development - Research and development expenses were reported at ¥7,884,151.19, slightly down from ¥8,008,843.89 in the previous period[27] Audit Information - The first quarter report was not audited[32]

Financial Performance - The company's revenue for 2024 reached ¥302,793,277.36, representing a 1.19% increase compared to ¥299,241,834.45 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥94,356,080.46, a 0.94% increase from ¥93,479,909.00 in 2023[17]. - The cash flow from operating activities increased by 32.49% to ¥142,114,578.87 in 2024, compared to ¥107,266,756.69 in 2023[17]. - The total assets at the end of 2024 were ¥1,915,597,694.39, reflecting a 5.83% increase from ¥1,810,100,800.90 at the end of 2023[17]. - The basic earnings per share for 2024 was ¥0.36, up 2.86% from ¥0.35 in 2023[17]. - In 2024, the company's total revenue reached ¥302,793,277.36, with a gross margin of 58.25%, an increase of 1.19% compared to 2023[69]. - Direct sales contributed ¥296,272,380.22 to the revenue, with a gross margin of 58.30%, up from 54.69% in 2023[69]. - The distribution model accounted for only 2.15% of total revenue in 2024, with sales of ¥6,520,897.14 and a gross margin of 56.15%[69]. - The company reported a significant increase in sales of animal and plant micro-ecological preparations, with sales volume up by 66.77% to 1,680.43 tons[90]. - The gross margin for edible probiotics was 65.92%, with a year-on-year increase of 19.80% in revenue[89]. Market and Industry Trends - The global probiotic market is projected to grow from $61.1 billion in 2021 to $91.1 billion by 2026, with a CAGR of 8.3%[29]. - The Asia-Pacific region accounts for approximately 44.4% of global probiotic consumption, significantly higher than Europe (23.5%) and North America (17.8%)[29]. - The domestic probiotic market in China was valued at approximately 879.8 billion yuan in 2020, with an annual growth rate of 11-12% expected[29]. - By 2027, the domestic probiotic market size is expected to reach 149.6 billion yuan, with local manufacturers accounting for 74.8 billion yuan[32]. - The demand for probiotic products is anticipated to maintain rapid growth in the coming years, driven by increasing health awareness among consumers[33]. - The domestic postbiotics market is in its early stages but is expected to experience explosive growth, becoming a significant segment within the probiotic industry[33]. Research and Development - The company has been focusing on the research and development of probiotic products, which falls under the food manufacturing industry[26]. - The company possesses a resource library of over 50,000 strains of lactic acid bacteria, enabling targeted development of functional foods and dietary supplements[53]. - The company has invested significantly in R&D, conducting numerous clinical trials in collaboration with top hospitals to validate the beneficial functions of its core strains[74]. - Research and development expenses for 2024 amounted to CNY 36.33 million, reflecting a 6.24% increase compared to the previous year[83]. - The company is developing a unique gut microbiome database for the Chinese population, which is expected to support the application research of probiotics and enhance product development[99]. Product Development and Innovation - The company has introduced innovative probiotic products targeting weight management and oral health, enhancing its competitive edge in the market[83]. - The dual-protein probiotic fermented milk product is being developed to improve competitiveness and increase sales, with a focus on high probiotic counts and superior flavor profiles[99]. - The company aims to develop a new product line of probiotic tea beverages that meet consumer health demands, with high sensory ratings and probiotic counts[99]. - The company is actively developing products in collaboration with downstream beverage and baking enterprises to meet market demands, which may lead to rapid growth in the compound food additive business[51]. Strategic Partnerships and Collaborations - The company has established long-term stable strategic partnerships with leading enterprises in the dairy and pharmaceutical industries, enhancing customer cooperation and product development[76]. - The company has maintained close strategic partnerships with major dairy producers, enhancing cooperation in product development and research[50]. - The company is focusing on the core industries of lactic acid bacteria and probiotics, while compound food additives will continue to play a supplementary role in overall business growth[51]. Governance and Compliance - The company has established strict confidentiality protocols to protect core technologies and product formulas from leaks[144]. - The company has established performance evaluation standards and incentive mechanisms, ensuring transparency and compliance with legal regulations[157]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[158]. - The company has a clear governance structure that aligns with regulatory requirements, ensuring no significant discrepancies[160]. Employee Management and Development - The total number of employees at the end of the reporting period is 295, with 26 in the parent company and 269 in major subsidiaries[199]. - The company emphasizes a compensation system based on job roles and performance, ensuring market competitiveness and internal fairness[200]. - Employee benefits include mandatory social insurance and housing fund contributions, along with various welfare policies tailored to employee needs[200]. - The company is committed to the interaction between human capital appreciation and corporate capital growth, aligning employee value with corporate development[200]. Future Outlook and Expansion Plans - The company plans to expand its market presence and enhance its product offerings in the food and feed additive sectors[26]. - The company aims to achieve a comprehensive solution and a full range of products by 2025, focusing on the steady growth of probiotics and the development of compound food additives as a key supplement to its main business[132]. - The company plans to expand its business operations following the establishment of new subsidiaries[117]. - The company is exploring new strategies for market expansion and product development in response to consumer demand[123].

第一创业证券承销保荐有限责任公司 关于北京科拓恒通生物技术股份有限公司 2024 年度内部控制自我评价报告的核查意见 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机 构"）作为北京科拓恒通生物技术股份有限公司（以下简称"科拓生物"或"公 司"）2022 年向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务 管理办法》《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定以及《企业 内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称 "企业内部控制规范体系"），对科拓生物《2024 年度内部控制自我评价报告》 进行了审慎核查，具体情况如下： 一、保荐机构进行的核查工作 一创投行保荐代表人通过与公司管理层及财务管理部、内部审计部等部门 的沟通交流，取得公司 2024 年度内部控制自我评价报告等相关信息资料；查阅 股东大会、董事会等会议记录、内部审计报告，以及各项业务和管理规则制度； 查阅公司董事会出具的 2024 年度内部控制自我评价报告，对公司内部控制的完 整、合理性及有效性进行了全面、认真的核查。 ...

第一创业证券承销保荐有限责任公司 关于北京科拓恒通生物技术股份有限公司 使用闲置募集资金进行现金管理的核查意见 一、募集资金基本情况 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机构"） 作为北京科拓恒通生物技术股份有限公司（以下简称"科拓生物"或"公司"） 2022 年向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办 法》《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关规定，对科拓生物使用闲 置募集资金进行现金管理的事项进行了审慎核查，具体情况如下： （一）首次公开发行股票 经中国证券监督管理委员会《关于核准北京科拓恒通生物技术股份有限公司 首次公开发行股票的批复》（证监许可[2020]1337 号）核准，公司首次公开发行 人民币普通股（A 股）2,063.00 万股，每股面值为人民币 1.00 元，每股发行价格 为 23.70 元，募集资金总额为人民币 48,893.10 万元，扣除不含税的发行费用 5,274.95 万元后，募集资金净额为人民币 43,618.15 万元。中审众环会计师事务 所（特殊普 ...

2024 年度募集资金存放与使用情况的核查意见 第一创业证券承销保荐有限责任公司 关于北京科拓恒通生物技术股份有限公司 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机 构"）作为北京科拓恒通生物技术股份有限公司（以下简称"科拓生物"或"公 司"）2022 年向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务 管理办法》《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，对科拓生 物 2024 年度募集资金存放与使用情况进行了审慎核查，具体情况如下： 一、募集资金基本情况 2、向特定对象发行股票 经中国证券监督管理委员会《关于同意北京科拓恒通生物技术股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2022〕3011 号）同意，公司 向特定对象发行人民币普通股（A 股）2,673.80 万股，每股发行价格为 26.18 元， 1 募集资金总额为人民币 70,000.00 万元，扣除不含税发行费用人民币 1,409.76 万 元后，公司实际募集资金净额为人民币 68,590.23 万元。上述募集资金总额扣除 尚 ...

2024 年度持续督导跟踪报告 | 保荐机构名称：第一创业证券承销保荐有限责任公司 | 被保荐公司简称：科拓生物 | | --- | --- | | 保荐代表人姓名：刘毅 | 联系电话：010-63212080 | | 保荐代表人姓名：李兴刚 | 联系电话：010-63212080 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 防止关联方占用公司资源的制度、募集资金管理制度、 | 是 | | 内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 12 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | 无，均事前 ...

本审核报告仅供北京科拓恒通生物技术股份有限公司 2024 年度年报披露之目的使用， 不得用作任何其他目的。 中审众环会计师事务所（特殊普通合伙） 中国注册会计师： 关于北京科拓恒通生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字（2025）0100766 号 北京科拓恒通生物技术股份有限公司全体股东： 我们接受委托，在审计了北京科拓恒通生物技术股份有限公司（以下简称"科拓生物公 司"）2024 年 12 月 31 日合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及 公司的现金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的 《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇 总表"）进行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号 ——上市公司资金往来、对外担保的监管要求》的规定，编制和披露汇总表、提供真实、合 法、完整的审核证据是科拓生物公司管理层的责任，我们的责任是在执行审核工作的基础上 对汇总表发表专项审核意见。 我们按照中国注册会计师审计准则的相关规定执行了 ...

关于北京科拓恒通生物技术股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 众环专字（2025）0100767 号 北京科拓恒通生物技术股份有限公司全体股东： 我们接受委托，对后附的北京科拓恒通生物技术股份有限公司（以下简称"科拓生物公 司"）截至 2024 年 12 月 31 日止的《董事会关于募集资金年度存放与实际使用情况的专项报 告》进行了鉴证工作。 按照中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》和深圳证券交易所颁布的《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关规定，编制《董事会关于募集资金年度存放与实际使用情况 的专项报告》，提供真实、合法、完整的实物证据、原始书面材料、副本材料、口头证言以 及我们认为必要的其他证据，是科拓生物公司董事会的责任。我们的责任是在执行鉴证工作 的基础上，对《董事会关于募集资金年度存放与实际使用情况的专项报告》发表鉴证意见。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号——历史财务信息审计或审阅 以外的鉴证业务》的规定执行了鉴证工作，该准则要求我们遵守中国注册会计师职业道德守 ...

内部控制审计报告 众环审字（2025）0101881 号 北京科拓恒通生物技术股份有限公司全体股东： 我们认为，北京科拓恒通生物技术股份有限公司于 2024 年 12 月 31 日按照《企业内部 控制基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 中审众环会计师事务所（特殊普通合伙） 中国注册会计师： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了北 京科拓恒通生物技术股份有限公司（以下简称"科拓生物公司"）2024 年 12 月 31 日的财务 报告内部控制的有效性。 一、科拓生物公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是科拓生物公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循 ...